Clinical Features, Strain Distribution, Antifungal Resistance and Prognosis of Patients with Non-albicans Candidemia: A Retrospective Observational Study

References

• PfallerMA, DiekemaDJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–163. doi:10.1128/CMR.00029-0617223626
   PubMed Web of Science ®Google Scholar
• LauschKR, SøgaardM, RosenvingeFS, et al. High incidence of candidaemia in a nationwide cohort: underlying diseases, risk factors and mortality. Int J Infect Dis. 2018;76:58–63. doi:10.1016/j.ijid.2018.08.01030176293
   PubMed Web of Science ®Google Scholar
• ColomboAL, NucciM, ParkBJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44(8):2816–2823. doi:10.1128/JCM.00773-0616891497
   PubMed Web of Science ®Google Scholar
• JiaX, LiC, CaoJ, WuX, ZhangL. Clinical characteristics and predictors of mortality in patients with candidemia: a Six-Year Retrospective Study. Eur J Clin Microbiol. 2018;37(9):1717–1724. doi:10.1007/s10096-018-3304-9
   Google Scholar
• CuervoG, Garcia-VidalC, Puig-AsensioM, et al. Usefulness of guideline recommendations for prognosis in patients with candidemia. Med Mycol. 2019;57(6):659–667. doi:10.1093/mmy/myy11830418567
   PubMed Web of Science ®Google Scholar
• LeeRA, ZurkoJC, CaminsBC, et al. Impact of infectious disease consultation on clinical management and mortality in patients with candidemia. Clin Infect Dis. 2019;68(9):1585–1587. doi:10.1093/cid/ciy84930281081
   PubMed Web of Science ®Google Scholar
• PfallerMA, DiekemaDJ, TurnidgeJD, CastanheiraM, JonesRN. Twenty years of the SENTRY antifungal surveillance program: results for candida species from 1997–2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–S94. doi:10.1093/ofid/ofy35830895218
   PubMed Web of Science ®Google Scholar
• XiaoM, ChenSC, KongF, et al. Distribution and antifungal susceptibility of candida species causing candidemia in china: an update from the CHIF-NET Study. J Infect Dis. 2020;221(Suppl 2):S139–S147. doi:10.1093/infdis/jiz57332176789
   PubMed Web of Science ®Google Scholar
• ChiH, YangY, ShangS, et al. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect. 2011;44(5):369–375. doi:10.1016/j.jmii.2010.08.01021524971
   PubMedGoogle Scholar
• ZhangW, SongX, WuH, ZhengR. Epidemiology, risk factors and outcomes of Candida albicans vs. non- albicans candidaemia in adult patients in Northeast China. Epidemiol Infect. 2019;147:e277–e277. doi:10.1017/s095026881900163831552814
   PubMed Web of Science ®Google Scholar
• DimopoulosG, NtzioraF, RachiotisG, ArmaganidisA, FalagasME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008;106(2):523–529. doi:10.1213/ane.0b013e318160726218227310
   PubMed Web of Science ®Google Scholar
• ZhongL, ZhangS, TangK, et al. Clinical characteristics, risk factors and outcomes of mixed Candida albicans/bacterial bloodstream infections. Bmc Infect Dis. 2020;20(1):1–810. doi:10.1186/s12879-020-05536-z
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard. 3rd ed. Wayne, PA: CLSI; 2008.
   Google Scholar
• Clinical and Laboratory Standards Institute. M60. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st ed. Wayne, PA: CLSI; 2018.
   Google Scholar
• MermelLA, AllonM, BouzaE, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;49(1):1–45. doi:10.1086/59937619489710
   PubMed Web of Science ®Google Scholar
• SeymourCW, LiuVX, IwashynaTJ, et al. Assessment of clinical criteria for sepsis. JAMA. 2016;315(8):762. doi:10.1001/jama.2016.028826903335
   PubMed Web of Science ®Google Scholar
• KimSH, YoonYK, KimMJ, SohnJW. Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections. Clin Microbiol Infect. 2013;19(1):62–68. doi:10.1111/j.1469-0691.2012.03906.x22651822
   PubMed Web of Science ®Google Scholar
• Garnacho-MonteroJ, Diaz-MartinA, Garcia-CabreraE, Ruiz Perez de PipaonM, Hernandez-CaballeroC, Lepe-JimenezJA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2012;68(1):206–213. doi:10.1093/jac/dks34722945914
   PubMed Web of Science ®Google Scholar
• PappasPG, KauffmanCA, AndesDR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ93326679628
   PubMed Web of Science ®Google Scholar
• LamothF, LockhartSR, BerkowEL, CalandraT. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl 1):i4–i13. doi:10.1093/jac/dkx44429304207
   PubMed Web of Science ®Google Scholar
• SongY, ChenX, YanY, WanZ, LiuW, LiR. Prevalence and antifungal susceptibility of pathogenic yeasts in china: a 10-Year Retrospective Study in a teaching hospital. Front Microbiol. 2020;11:1410. doi:10.3389/fmicb.2020.0140132670247
   PubMed Web of Science ®Google Scholar
• PappasPG, LionakisMS, ArendrupMC, Ostrosky-ZeichnerL, KullbergBJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4(1):18026. doi:10.1038/nrdp.2018.2629749387
   PubMed Web of Science ®Google Scholar
• TanTY, HsuLY, AlejandriaMM, et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol. 2016;54(5):471–477. doi:10.1093/mmy/myv11426868904
   PubMed Web of Science ®Google Scholar
• EnochDA, YangH, AliyuSH, MicallefC. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65. doi:10.1007/978-1-4939-6515-1_227837497
   PubMedGoogle Scholar
• PerlinDS, Rautemaa-RichardsonR, Alastruey-IzquierdoA. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e392. doi:10.1016/S1473-3099(17)30316-X28774698
   PubMed Web of Science ®Google Scholar
• ApisarnthanarakA, NaknarongkijN, KiratisinP, MundyLM. Risk factors and outcomes of Candida albicans and non-albicans Candida species at a Thai tertiary care center. Am J Infect Control. 2009;37(9):781–782. doi:10.1016/j.ajic.2009.04.28919874981
   PubMed Web of Science ®Google Scholar
• VigourouxS, MorinO, MoreauP, HarousseauJL, MilpiedN. Candidemia in patients with hematologic malignancies: analysis of 7 years’ experience in a single center. Haematologica. 2006;91(5):717–718.16670081
   PubMed Web of Science ®Google Scholar
• HornDL, NeofytosD, AnaissieEJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695–1703. doi:10.1086/59903919441981
   PubMed Web of Science ®Google Scholar
• ViscoliC, GirmeniaC, MarinusA, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28(5):1071–1079. doi:10.1086/51473110452637
   PubMed Web of Science ®Google Scholar
• ChenXC, XuJ, WuDP. Clinical characteristics and outcomes of breakthrough candidemia in 71 hematologic malignancy patients and/or allogeneic hematopoietic stem cell transplant recipients: a Single-Center Retrospective Study from China, 2011–2018. Clin Infect Dis. 2020;71(Suppl4):S394–S399. doi:10.1093/cid/ciaa152333367573
   PubMed Web of Science ®Google Scholar
• WalshTJ, MerzWG. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol. 1986;85(4):498–502. doi:10.1093/ajcp/85.4.4983953503
   PubMed Web of Science ®Google Scholar
• Ben-AmiR, Olshtain-PopsK, KriegerM, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56(5):2518–2523. doi:10.1128/AAC.05947-1122314534
   PubMed Web of Science ®Google Scholar
• FanX, XiaoM, ZhangD, et al. Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China. Clin Microbiol Infect. 2019;25(7):885–891. doi:10.1016/j.cmi.2018.11.00730472420
   PubMed Web of Science ®Google Scholar
• AndesDR, SafdarN, BaddleyJW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–1122. doi:10.1093/cid/cis02122412055
   PubMed Web of Science ®Google Scholar
• DonaduMG, UsaiD, MarchettiM, et al. Antifungal activity of oils macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. Nat Prod Res. 2020;34(22):3280–3284. doi:10.1080/14786419.2018.155717530676066
   PubMed Web of Science ®Google Scholar
• DonaduMG, Peralta-RuizY, UsaiD, et al. Colombian essential oil of ruta graveolens against nosocomial antifungal resistant candida strains. J Fungi (Basel). 2021;7(5):383. doi:10.3390/jof705038334069001
   PubMedGoogle Scholar
• HamdyR, FayedB, HamodaAM, Rawas-QalajiM, HaiderM, SolimanSSM. Essential oil-based design and development of novel anti-candida azoles formulation. Molecules. 2020;25(6):1463. doi:10.3390/molecules25061463
   PubMed Web of Science ®Google Scholar
• BonaE, CantamessaS, PavanM, et al. Sensitivity of Candida albicans to essential oils: are they an alternative to antifungal agents?J Appl Microbiol. 2016;121(6):1530–1545. doi:10.1111/jam.1328227568869
   PubMed Web of Science ®Google Scholar